Protein citrullination as a link between periodontal diseases and rheumatoid art...
Protein citrullination as a link between periodontal diseases and rheumatoid arthritis RA and target for development of novel drugs to treat RA
Autoimmunity in rheumatoid arthritis (RA) is characterised by an antibody response to citrullinated proteins. Periodontitis (PD) is largely caused by infection, in which
Porphyromonas gingivalis is a major pathogen. The two diseas...
ver más
31/10/2014
HVL
8M€
Presupuesto del proyecto: 8M€
Líder del proyecto
HOGSKULEN PA VESTLANDET
No se ha especificado una descripción o un objeto social para esta compañía.
Fecha límite participación
Sin fecha límite de participación.
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto GUMS AND JOINTS
Líder del proyecto
HOGSKULEN PA VESTLANDET
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
8M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Autoimmunity in rheumatoid arthritis (RA) is characterised by an antibody response to citrullinated proteins. Periodontitis (PD) is largely caused by infection, in which
Porphyromonas gingivalis is a major pathogen. The two diseases combine specific HLA-DRB1alleles and smoking as risk factors, and have a similar pathophysiology characterised by destructive inflammation. A possible causative link between RA and PD is based on the ability of P. gingivalis to citrullinate proteins and thereby generate autoantigens that drive autoimmunity in RA. We hypothesise that anti-citrullinated protein antibodies can be generated, in genetically susceptible individuals, as a consequence of P. Gingivalis-induced citrullination in the gingiva. In the context of genetic risk factors, during chronic exposure to danger signals, such as bacterial
lipopolysacharides and DNA, tolerance to citrullinated proteins may be broken, with production of a pathogenic antibody response, which at a later time point cross-reacts with joint proteins and causes chronic RA. We will use a multidisciplinary approach (genetics, epidemiology, molecular immunology and animal models) to study susceptibility factors and immune responses in RA and PD, with an aim to identify novel etiological and pathogenic pathways, forming the basis for new therapies.